GlassScriptPhysician profile
John A Jernigan
NPI 1881635480
$25,099.17
in general payments reported to CMS, 2019-2025
55 companies · $2,034 in 2025
The $2,034 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,228 · 2020: $6,107 · 2021: $2,055 · 2022: $2,455 · 2023: $3,247 · 2024: $2,973 · 2025: $2,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,253.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,251.01 | 2019-2025 | Breztri, Wainua, Farxiga |
| Novo Nordisk INC | $2,419.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,589.99 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,452.13 | 2019-2025 | |
| Pfizer INC. | $1,322.11 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,307.99 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $1,039.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $975.05 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Sanofi-Aventis U.S. LLC | $865.29 | 2019-2023 | |
| Glaxosmithkline, LLC. | $774.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $743.02 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $716.61 | 2022-2025 | Amvuttra |
| Abbott Laboratories | $567.85 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $526.92 | 2019-2025 | Uplizna, Evenity, Prolia |
| Arbor Pharmaceuticals, INC. | $509.51 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jernigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.